The study by Pilati et al1 presents a comprehensive molecular characterization of ERBB2 in stage III colon cancer, proposing a novel classification integrating RNA and DNA analyses. Although this work advances our understanding of ERBB2 heterogeneity, several critical limitations in methodology and interpretation require urgent attention to ensure clinical translatability.
We will be happy to hear your thoughts